BEAM

Beam Therapeutics (BEAM)

Beam Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:BEAM

<< 이전 1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2022/01/24	22:40	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:BEAM	Beam Therapeutics Inc
2022/01/10	20:48	Dow Jones News	Pfizer, Beam Therapeutics Form Multi-Target Research Collaboration	NASDAQ:BEAM	Beam Therapeutics Inc
2022/01/10	20:46	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:BEAM	Beam Therapeutics Inc
2022/01/10	20:00	GlobeNewswire Inc.	Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases	NASDAQ:BEAM	Beam Therapeutics Inc
2022/01/10	20:00	Business Wire	Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases	NASDAQ:BEAM	Beam Therapeutics Inc
2022/01/09	23:00	GlobeNewswire Inc.	Beam Therapeutics Reports Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones	NASDAQ:BEAM	Beam Therapeutics Inc
2022/01/03	20:30	GlobeNewswire Inc.	Beam Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference	NASDAQ:BEAM	Beam Therapeutics Inc
2021/12/31	08:00	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:BEAM	Beam Therapeutics Inc
2021/12/24	08:01	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:BEAM	Beam Therapeutics Inc
2021/12/23	08:00	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:BEAM	Beam Therapeutics Inc
2021/12/12	23:00	GlobeNewswire Inc.	Beam Therapeutics Outlines Long-term Strategy for Base Editing Programs in Sickle Cell Disease and Provides Preclinical Data Updates at ASH	NASDAQ:BEAM	Beam Therapeutics Inc
2021/11/12	21:00	GlobeNewswire Inc.	Beam Therapeutics Reports Preclinical Data Highlighting Multiplex Base Editing Approach to Create Anti-CD5 CAR T-cell Investigational Therapies for T-Cell Malignancies	NASDAQ:BEAM	Beam Therapeutics Inc
2021/11/11	20:30	GlobeNewswire Inc.	Beam Therapeutics to Participate in the Jefferies 2021 Virtual London Healthcare Conference	NASDAQ:BEAM	Beam Therapeutics Inc
2021/11/08	22:32	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:BEAM	Beam Therapeutics Inc
2021/11/08	20:19	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:BEAM	Beam Therapeutics Inc
2021/11/08	20:00	GlobeNewswire Inc.	Beam Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to its Board of Directors	NASDAQ:BEAM	Beam Therapeutics Inc
2021/11/08	20:00	GlobeNewswire Inc.	Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial Results	NASDAQ:BEAM	Beam Therapeutics Inc
2021/11/04	22:40	GlobeNewswire Inc.	Beam Therapeutics Announces Upcoming Preclinical Data Presentations at the American Society of Hematology Annual Meeting	NASDAQ:BEAM	Beam Therapeutics Inc
2021/10/20	19:30	GlobeNewswire Inc.	Beam Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit	NASDAQ:BEAM	Beam Therapeutics Inc
2021/10/19	22:00	GlobeNewswire Inc.	Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs	NASDAQ:BEAM	Beam Therapeutics Inc
2021/10/19	19:30	GlobeNewswire Inc.	Beam Therapeutics Announces Preclinical Data Highlighting Base Editing Approach to Correct a Glycogen Storage Disease Type Ia Disease-Causing Mutation	NASDAQ:BEAM	Beam Therapeutics Inc
2021/10/09	05:22	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:BEAM	Beam Therapeutics Inc
2021/10/01	21:43	GlobeNewswire Inc.	Beam Therapeutics to Present Preclinical Data Highlighting Potential of CAR T Multiplex Base Editing Approach Targeting CD5 at 2021 SITC Annual Meeting	NASDAQ:BEAM	Beam Therapeutics Inc
2021/09/28	19:30	GlobeNewswire Inc.	Beam Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference	NASDAQ:BEAM	Beam Therapeutics Inc
2021/09/27	19:30	GlobeNewswire Inc.	Beam Therapeutics Announces Preclinical Data Highlighting Potential of Base Editors to Target Disease Drivers of Chronic Hepatitis B Infection	NASDAQ:BEAM	Beam Therapeutics Inc
2021/09/23	19:30	GlobeNewswire Inc.	Beam Therapeutics Announces Updated Preclinical Data Highlighting Optimized LNP Delivery Approaches for In Vivo Base Editing to the Liver and Other Tissues	NASDAQ:BEAM	Beam Therapeutics Inc
2021/09/22	07:01	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:BEAM	Beam Therapeutics Inc
2021/09/22	07:00	Edgar (US Regulatory)	Amended Statement of Changes in Beneficial Ownership (4/a)	NASDAQ:BEAM	Beam Therapeutics Inc
2021/09/22	07:00	Edgar (US Regulatory)	Amended Statement of Changes in Beneficial Ownership (4/a)	NASDAQ:BEAM	Beam Therapeutics Inc
2021/09/08	19:30	GlobeNewswire Inc.	Beam Therapeutics to Participate in the 2021 Wells Fargo Virtual Healthcare Conference	NASDAQ:BEAM	Beam Therapeutics Inc